Effect of altered gastric emptying and gastrointestinal motility on metformin absorption

Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subjec...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 50; no. 4; pp. 325 - 332
Main Authors Marathe, Punit H., Wen, Yandong, Norton, Jean, Greene, Douglas S., Barbhaiya, Rashmi H., Wilding, Ian R.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.10.2000
Blackwell Science
Blackwell Science Inc
Subjects
Online AccessGet full text
ISSN0306-5251
1365-2125
DOI10.1046/j.1365-2125.2000.00264.x

Cover

Loading…
Abstract Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Results Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Conclusions Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.
AbstractList The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. An open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.
Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Results Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Conclusions Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.
Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. Methods An open‐label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99m Tc‐DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings. Results Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half‐life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,∞) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival. Conclusions Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.AIMSThe purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects.An open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.METHODSAn open-label, three treatment, three period crossover study was conducted in 11 healthy volunteers. Each subject received 550 mg metformin hydrochloride in solution alone; 5 min after a 10 mg i.v. dose of metoclopramide; and 30 min after a 30 mg oral dose of propantheline. Metformin solution was radiolabeled by the addition of 99mTc-DTPA. The gastrointestinal transit of the solution was monitored by gamma scintigraphy and the pharmacokinetic data were correlated with the scintigraphic findings.Scintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.RESULTSScintigraphic data indicated that pretreatment with metoclopramide decreased gastric emptying time and increased gastrointestinal motility while pretreatment with propantheline had the opposite effect. The systemic disposition of metformin was not altered by pretreatment with metoclopramide and propantheline, as judged by unchanged renal clearance and elimination half-life of metformin. Extent of metformin absorption was essentially unchanged after pretreatment with metoclopramide. However, AUC(0,infinity) and % UR (percent dose excreted unchanged in urine) generally increased with increase in gastric emptying time and small intestinal transit times. GI overlay plots showed that the absorption phase of metformin plasma profile always coincided with gastric emptying and the beginning of decline of metformin plasma concentrations was usually associated with the colon arrival. Only in cases where the intestinal transit was drastically prolonged by propantheline pretreatment, was a decline in plasma levels observed prior to colon arrival.Metformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.CONCLUSIONSMetformin is primarily absorbed from the small intestine. The extent of metformin absorption is improved when the gastrointestinal motility is slowed. These findings have significant implications in the design of a metformin modified release dosage form.
Author Wen, Yandong
Barbhaiya, Rashmi H.
Marathe, Punit H.
Norton, Jean
Greene, Douglas S.
Wilding, Ian R.
Author_xml – sequence: 1
  givenname: Punit H.
  surname: Marathe
  fullname: Marathe, Punit H.
– sequence: 2
  givenname: Yandong
  surname: Wen
  fullname: Wen, Yandong
– sequence: 3
  givenname: Jean
  surname: Norton
  fullname: Norton, Jean
– sequence: 4
  givenname: Douglas S.
  surname: Greene
  fullname: Greene, Douglas S.
– sequence: 5
  givenname: Rashmi H.
  surname: Barbhaiya
  fullname: Barbhaiya, Rashmi H.
– sequence: 6
  givenname: Ian R.
  surname: Wilding
  fullname: Wilding, Ian R.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1500685$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11012555$$D View this record in MEDLINE/PubMed
BookMark eNqNUU1vFCEYJqbGbqt_wXAw3mb6wgCdTYyJbqo1aaIHTbwRhoGVDQMrsNr99zJ23aoXPUF4ny_e5wydhBgMQphAS4CJi01LOsEbSihvKQC0AFSw9vYBWhwHJ2gBHYiGU05O0VnOGwDSEcEfoVNCoCI4X6DPV9YaXXC0WPlikhnxWuWSnMZm2pa9C2uswuExulBMLi4oj6dYnHdlj2PAkyk2pskFrIYc07a4GB6jh1b5bJ4cznP06c3Vx9V1c_P-7bvVq5tGc8FYMxrLwA5q7NmyF2xUy5q517QbFBvoZc2uteAd45wYwtmoR0YJN8uh7xUFrbtz9PJOd7sbJjNqE0pSXm6Tm1Tay6ic_HMS3Be5jt8kBcIBWBV4fhBI8euufk9OLmvjvQom7rK8pHTZ9ZxU4NPfnY4Wv5ZZAc8OAJW18japoF2-x1U70fP7xDrFnJOxUrui5p3VfM5LAnIuWW7k3KWcu5RzyfJnyfK2CvR_CRwt_k19cUf97rzZ_zdPvl59qJfuB64iv9w
CODEN BCPHBM
CitedBy_id crossref_primary_10_4236_pp_2024_1512025
crossref_primary_10_1002_jps_21794
crossref_primary_10_1016_j_jddst_2017_09_013
crossref_primary_10_1016_S1359_6446_04_03351_3
crossref_primary_10_3390_pharmaceutics13111873
crossref_primary_10_3109_10717544_2015_1089957
crossref_primary_10_1007_s13318_014_0213_x
crossref_primary_10_1177_00912700122010546
crossref_primary_10_1007_s00125_015_3844_9
crossref_primary_10_52711_0974_360X_2023_00814
crossref_primary_10_1208_s12249_018_1070_8
crossref_primary_10_3390_molecules22020214
crossref_primary_10_1111_jphp_12516
crossref_primary_10_1136_spcare_2023_004248
crossref_primary_10_1016_j_ijpharm_2016_11_063
crossref_primary_10_1016_j_jddst_2020_102054
crossref_primary_10_2165_11534750_000000000_00000
crossref_primary_10_2165_00024677_200403050_00008
crossref_primary_10_1016_j_jpba_2007_07_018
crossref_primary_10_1016_j_xphs_2016_11_009
crossref_primary_10_1208_s12249_009_9332_0
crossref_primary_10_1016_j_ejpb_2010_03_009
crossref_primary_10_1007_s40495_020_00230_9
crossref_primary_10_1007_s11095_022_03280_4
crossref_primary_10_1097_FTD_0b013e3181b385ba
crossref_primary_10_1111_cts_12780
crossref_primary_10_2337_diacare_29_04_06_dc05_1967
crossref_primary_10_1002_psp4_13228
crossref_primary_10_1080_17425247_2021_1825375
crossref_primary_10_1007_s40262_019_00756_2
crossref_primary_10_1007_s13318_017_0418_x
crossref_primary_10_1038_s41598_019_53996_4
crossref_primary_10_3109_03639045_2015_1096279
crossref_primary_10_1002_bdd_615
crossref_primary_10_1111_bcp_13049
crossref_primary_10_1016_j_clinthera_2007_05_013
crossref_primary_10_1038_s41467_021_27762_y
crossref_primary_10_1016_j_ijpharm_2003_09_047
crossref_primary_10_1248_cpb_58_1295
crossref_primary_10_1371_journal_pone_0249594
crossref_primary_10_1016_j_ejpb_2018_03_002
crossref_primary_10_1124_dmd_119_088435
crossref_primary_10_1177_0091270007300949
crossref_primary_10_1002_admt_202200731
crossref_primary_10_1210_endocr_bqad139
crossref_primary_10_1016_j_clinthera_2011_10_003
crossref_primary_10_1016_j_ejps_2024_106853
crossref_primary_10_2174_1389200220666191023105609
crossref_primary_10_1007_s40264_014_0223_2
crossref_primary_10_1111_j_1464_5491_2005_01769_x
crossref_primary_10_5138_ijdd_2010_0975_0215_02022
crossref_primary_10_2174_0929867329666220820151959
crossref_primary_10_1007_s00592_022_01890_3
crossref_primary_10_1021_jm030999b
crossref_primary_10_2165_00003088_200544070_00004
crossref_primary_10_1007_s12010_021_03667_w
crossref_primary_10_1016_j_arr_2024_102439
crossref_primary_10_1016_j_ejpb_2019_02_022
crossref_primary_10_1016_S1773_2247_10_50079_0
crossref_primary_10_2337_dc10_2140
crossref_primary_10_1016_j_carbpol_2012_05_089
crossref_primary_10_1016_j_ejpb_2007_06_004
crossref_primary_10_1016_j_ijpharm_2013_03_043
crossref_primary_10_1002_jps_23629
crossref_primary_10_3390_pharmaceutics13050698
crossref_primary_10_1016_j_ejps_2004_03_016
crossref_primary_10_1088_1757_899X_263_2_022030
crossref_primary_10_1007_s40262_017_0532_6
crossref_primary_10_1016_j_ejps_2016_08_060
crossref_primary_10_1016_j_vascn_2013_02_001
crossref_primary_10_1016_j_ijbiomac_2012_10_033
crossref_primary_10_1177_0091270004274432
crossref_primary_10_1248_bpb_b24_00566
crossref_primary_10_1371_journal_pone_0191258
crossref_primary_10_1007_s10924_019_01646_1
crossref_primary_10_1016_j_ejpb_2004_03_001
crossref_primary_10_1016_j_ijpharm_2010_04_046
crossref_primary_10_3109_10837450_2011_604783
crossref_primary_10_5487_TR_2013_29_3_173
crossref_primary_10_3109_03639045_2015_1058815
crossref_primary_10_5937_scriptamed51_25521
crossref_primary_10_1185_03007990903094361
crossref_primary_10_3389_fnut_2021_742656
crossref_primary_10_15406_japlr_2017_05_00130
crossref_primary_10_1186_s12906_017_1809_x
Cites_doi 10.1007/BF01059558
10.1111/j.1365-2125.1981.tb01206.x
10.1002/j.1552-4604.1992.tb03876.x
10.1002/j.1552-4604.1993.tb05612.x
10.1007/BF00315510
10.2165/00003088-199630050-00003
10.1023/A:1015849700421
10.2165/00003495-197612020-00001
10.2165/00003088-199427060-00004
10.1023/A:1015858829187
10.1023/A:1018959732744
ContentType Journal Article
Copyright 2000 INIST-CNRS
2000 Blackwell Science Ltd 2000
Copyright_xml – notice: 2000 INIST-CNRS
– notice: 2000 Blackwell Science Ltd 2000
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1046/j.1365-2125.2000.00264.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2125
EndPage 332
ExternalDocumentID PMC2015004
11012555
1500685
10_1046_j_1365_2125_2000_00264_x
BCP264
Genre article
Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c5644-def40fbad849864da93068c23ba4b27251cc6534551e154dcd4215e9b88a20cc3
IEDL.DBID DR2
ISSN 0306-5251
IngestDate Thu Aug 21 18:17:57 EDT 2025
Fri Jul 11 15:34:49 EDT 2025
Wed Feb 19 02:34:36 EST 2025
Mon Jul 21 09:15:52 EDT 2025
Tue Jul 01 01:47:34 EDT 2025
Thu Apr 24 23:08:47 EDT 2025
Wed Jan 22 17:05:35 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Hypoglycemic agent
Biguanides
Motility
Healthy subject
Oral administration
Gastric emptying
Metformin
Gastrointestinal
Metabolism
Pharmacokinetics
Digestive transit
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5644-def40fbad849864da93068c23ba4b27251cc6534551e154dcd4215e9b88a20cc3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00264.x
PMID 11012555
PQID 72293851
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2015004
proquest_miscellaneous_72293851
pubmed_primary_11012555
pascalfrancis_primary_1500685
crossref_citationtrail_10_1046_j_1365_2125_2000_00264_x
crossref_primary_10_1046_j_1365_2125_2000_00264_x
wiley_primary_10_1046_j_1365_2125_2000_00264_x_BCP264
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2000
PublicationDateYYYYMMDD 2000-10-01
PublicationDate_xml – month: 10
  year: 2000
  text: October 2000
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: London
– name: England
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 2000
Publisher Blackwell Science Ltd
Blackwell Science
Blackwell Science Inc
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell Science
– name: Blackwell Science Inc
References 1993; 45
1992; 9
1976; 12
1993; 33
1993; 10
1984; 12
1996; 30
1994; 27
1982
1991
1992; 32
1991; 8
1981; 12
1996; 6
1983; 34
e_1_2_5_14_2
e_1_2_5_9_2
e_1_2_5_16_2
e_1_2_5_8_2
e_1_2_5_15_2
e_1_2_5_7_2
e_1_2_5_10_2
e_1_2_5_6_2
e_1_2_5_12_2
Newman SP (e_1_2_5_13_2) 1996; 6
e_1_2_5_4_2
e_1_2_5_11_2
e_1_2_5_3_2
e_1_2_5_2_2
Osmen MA (e_1_2_5_5_2) 1983; 34
References_xml – year: 1982
– volume: 6
  start-page: 21
  year: 1996
  end-page: 33
  article-title: The importance of gamma scintigraphy in pharmaceutical development
  publication-title: J Pharm Med
– volume: 10
  start-page: 709
  year: 1993
  end-page: 714
  article-title: Absorption, gastrointestinal transit, and tablet erosion of felodipine extended‐release (ER) tablets
  publication-title: Pharm Res
– volume: 32
  start-page: 725
  year: 1992
  end-page: 731
  article-title: Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers
  publication-title: J Clin Pharmacol
– volume: 34
  start-page: 404
  year: 1983
  end-page: 408
  article-title: Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide
  publication-title: Curr Ther Res
– volume: 12
  start-page: 649
  year: 1984
  end-page: 655
  article-title: An exact confidence interval from untransformed data for the ratio of two treatment means
  publication-title: J Pharmacokin Biopharm
– volume: 8
  start-page: 360
  year: 1991
  end-page: 364
  article-title: Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects
  publication-title: Pharm Res
– volume: 30
  start-page: 359
  year: 1996
  end-page: 371
  article-title: Clinical pharmacokinetics of metformin
  publication-title: Clin Pharmacokin
– volume: 9
  start-page: 1436
  year: 1992
  end-page: 1441
  article-title: evaluation of enteric‐coated naproxen tablets using gamma scintigraphy
  publication-title: Pharm Res
– volume: 12
  start-page: 235
  year: 1981
  end-page: 246
  article-title: Metformin kinetics in healthy subjects and patients with diabetes mellitus
  publication-title: Br J Clin Pharmacol
– volume: 33
  start-page: 712
  year: 1993
  end-page: 718
  article-title: Localization of drug release sites from an oral sustained‐release formulation of 5‐ASA (Pentasa ) in the gastrointestinal tract using gamma scintigraphy
  publication-title: J Clin Pharmacol
– volume: 12
  start-page: 81
  year: 1976
  end-page: 131
  article-title: Metoclopramide. A review of its pharmacological properties and clinical use
  publication-title: Drugs
– year: 1991
– volume: 45
  start-page: 409
  year: 1993
  end-page: 413
  article-title: Effect of metoclopramide and loperamide on the pharmacokinetics of didanosine in HIV seropositive male and female patients
  publication-title: Eur J Clin Pharmacol
– volume: 27
  start-page: 447
  year: 1994
  end-page: 461
  article-title: Pharmacokinetic drug interactions with gastrointestinal motility modifying agents
  publication-title: Clin Pharmacokin
– volume: 6
  start-page: 21
  year: 1996
  ident: e_1_2_5_13_2
  article-title: The importance of gamma scintigraphy in pharmaceutical development
  publication-title: J Pharm Med
– ident: e_1_2_5_16_2
  doi: 10.1007/BF01059558
– volume: 34
  start-page: 404
  year: 1983
  ident: e_1_2_5_5_2
  article-title: Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide
  publication-title: Curr Ther Res
– ident: e_1_2_5_2_2
  doi: 10.1111/j.1365-2125.1981.tb01206.x
– ident: e_1_2_5_8_2
  doi: 10.1002/j.1552-4604.1992.tb03876.x
– ident: e_1_2_5_10_2
  doi: 10.1002/j.1552-4604.1993.tb05612.x
– ident: e_1_2_5_15_2
– ident: e_1_2_5_7_2
  doi: 10.1007/BF00315510
– ident: e_1_2_5_14_2
– ident: e_1_2_5_3_2
  doi: 10.2165/00003088-199630050-00003
– ident: e_1_2_5_11_2
  doi: 10.1023/A:1015849700421
– ident: e_1_2_5_6_2
  doi: 10.2165/00003495-197612020-00001
– ident: e_1_2_5_4_2
  doi: 10.2165/00003088-199427060-00004
– ident: e_1_2_5_9_2
  doi: 10.1023/A:1015858829187
– ident: e_1_2_5_12_2
  doi: 10.1023/A:1018959732744
SSID ssj0013165
Score 1.9687085
Snippet Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin...
Aims The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin...
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 325
SubjectTerms absorption
Adult
Biological and medical sciences
Cross-Over Studies
Dopamine Agonists - pharmacology
Drug Interaction
Drug Interactions
Female
gamma scintigraphy
Gastric Emptying - physiology
gastrointestinal motility
Gastrointestinal Motility - physiology
Hormones. Endocrine system
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - pharmacokinetics
Intestinal Absorption - physiology
Male
Medical sciences
metformin
Metformin - adverse effects
Metformin - pharmacokinetics
Metoclopramide - pharmacology
Muscarinic Antagonists - pharmacology
Pharmacology. Drug treatments
Propantheline - pharmacology
Title Effect of altered gastric emptying and gastrointestinal motility on metformin absorption
URI https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1365-2125.2000.00264.x
https://www.ncbi.nlm.nih.gov/pubmed/11012555
https://www.proquest.com/docview/72293851
https://pubmed.ncbi.nlm.nih.gov/PMC2015004
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA_ikyB-f0yd5kF8smNtkrV91KH4ATJEYW8lTVIVtR2uA_Wv9y7pVqc-iPg21t7WXO6SX3N3vyNkH7YVybkQXqaN9nimwediozyf6bgTphmaDWZbXHXObvlFX_Sr_CeshXH8EJMDN_QMu16jg8vUdSFpW3bbcYYW7NC23gSPRjq8hXgSLyA-ug7qgIJvu0oiQoZ3L-FXST1VgPPHH5raqeYHcghKy1y3i5_g6Pesys9o125Xp4vkcTxQl6Xy2BqVaUu9f-GA_B9NLJGFCtXSI2eGy2TG5CvkoOdosd8O6U1d5TU8pAe0VxNmv62SvqNQpkVGbfDeaHonsZ-IouZ5UGIhFpV59WWBBBewLuH_YSIhvkbQIqfPpkT8_ZBTeOzixa6Ea-T29OSme-ZVHR88JQCYedqAcWSp1BFH2ngtY5ivSAUslTwNQpg3pTqCgW35BrCfVpoDZDFxGkUyaCvF1slsXuRmk1CdhRKWLyNNFHDGAAa2RRayWGnDmOGiQcLx7CaqokPHrhxPiQ3LcyxhQ7UmqFZs1ok0qqDW5LVB_InkwFGC_EKmOWVAtaDAIh14mr2xQSXg3xi0kbkpRsMkDACQASxukA1nXrUoUrMJgSOZMrzJDcgcPn0lf7i3DOIBnnO1eYMIa1e_HkZy3O3Bh60_ym2TOctkYHMhd8hs-TIyTcB0ZboL3np-uWt99gMzAz__
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1RT9swED4h9rBJ08bYxrrB8APiiXRNbDfJI7ChbgNUTUXqW-TYDqBBUtFUGvv1u7PTZmU8oIm3qu0l8fnO_uK7-w5gB7cVJYSUQWGsCURh0OdSq4OQm7Qf5wWZDWVbnPYHZ-LbWI6bdkBUC-P5IRYHbuQZbr0mB6cD6U9NWNJ7uUvRwi3aFZzQ2UhfdBFQPqEG39TO4POPqA0phK6vJGFkfPuSYZPW04Q4773S0l71fKKmqLbC97u4D5D-m1f5N951G9bRS7iaD9Xnqfzszuq8q3_fYYF8JF2swYsG2LJ9b4mvYMWW67A79MzYt3ts1BZ6TffYLhu2nNm3r2HsWZRZVTAXv7eGnStqKaKZvZ7UVIvFVNl8WRHHBS5NdD_KJaQ3CVaV7NrWBMEvS6byaXXjFsM3cHb0ZXQ4CJqmD4GWiM0CY9E-ilyZRBBzvFEpTliiI54rkUcxTpzWfcnRvEKL8M9oIxC12DRPEhX1tOZvYbWsSvsOmClihSuYVTaJBOeIBHuyiHmqjeXcCtmBeD69mW4Y0akxx1XmIvOCqthIrRmplfp1EpMqqjX71YFwITnxrCAPkNlasqBWUFKdDj7N9tyiMnRxituo0lazaRZHiMkQGXdgw9tXK0rsbFLSSJYsb_EHIg9f_qW8vHAk4hEddfVEB6QzrAcPIzs4HOKH9_8ptw1PB6OT4-z46-n3D_DMERu41MhNWK1vZnYLIV6df3Su-weNK0Mg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB6hIiEkBOUd2tI9oJ7qEHt3_ThCISoPVRFqpdys9T5KVWpHjSNRfn1ndp2YQA8V4hYlGds7O7P7eWfmG4A3uK0oIaSMnLEmEs6gzxVWRzE3RZpVjsyGsi2O0sMT8Xkqp13-E9XCBH6I1YEbeYZfr8nBZ8a97aKSwcl9hhbu0L7ehI5GUjFEPHlXpOg7BJC-JX1EIfZtJQki48uXjLusni7CeeOV1raqBzM1R6250O7iJjz6d1rl73DX71fjR3C-HGlIUzkfLtpqqH_9QQL5f1SxCQ87WMveBTt8DHds_QT2JoEX-2qfHfdlXvN9tscmPWP21VOYBg5l1jjmo_fWsFNFDUU0sxezliqxmKq7LxtiuMCFie5HmYT0HsGaml3YlgD4Wc1UNW8u_VL4DE7GH48PDqOu5UOkJSKzyFi0DlcpkwvijTeqwPnKdcIrJaokw3nTOpUcjSu2CP6MNgIxiy2qPFfJSGv-HDbqprYvgRmXKVy_rLJ5IjhHHDiSLuOFNpZzK-QAsuXslrrjQ6e2HD9KH5cXVMNGai1JrdStk3hUUa3lzwHEK8lZ4AS5hczOmgH1gpKqdPBpdpcGVaKDU9RG1bZZzMssQUSGuHgAL4J59aLEzSYljWTN8FZ_IOrw9V_qs--eQjyhg66RGID0dnXrYZTvDyb44dU_yu3CvcmHcfn109GXLbjvWQ18XuQ2bLSXC7uD-K6tXnvHvQalekHY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+altered+gastric+emptying+and+gastrointestinal+motility+on+metformin+absorption&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Marathe%2C+P+H&rft.au=Wen%2C+Y&rft.au=Norton%2C+J&rft.au=Greene%2C+D+S&rft.date=2000-10-01&rft.issn=0306-5251&rft.volume=50&rft.issue=4&rft.spage=325&rft_id=info:doi/10.1046%2Fj.1365-2125.2000.00264.x&rft_id=info%3Apmid%2F11012555&rft.externalDocID=11012555
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon